Recent advances in the treatment of the spondyloarthropathies

Current Opinion in Rheumatology

Volumn 16, Issue 4, 2004, Pages 357-365

  Liu, Yan ^a   Cortinovis, Daniela ^a   Stone, Millicent A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; MONOCLONAL ANTIBODY CD3; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FOLLOW UP; FRACTURE; HUMAN; INFECTION; INJECTION SITE; KINESIOTHERAPY; LEUKOPENIA; LONG TERM CARE; MYALGIA; NEUROPATHY; OSTEOPOROSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SPA TREATMENT; SPONDYLOARTHROPATHY; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042619853     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000129719.21563.35     Document Type: Review

References (86)

1. Braun J, Bollow M, Remlinger G, et al.: Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41:58-67.
2. van den Linden SM, Valkenburg HA, Jongh BM, et al.: The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984, :241-249.
3. Zink A, Braun J, Listing J, et al.: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. J Rheumatol 2000, 27:613-622.
4. Carette S, Graham D, Little H, et al.: The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983, 26:186-190.
5. Helliwell P, Abbott CA, Chamberlain MA: A randomized trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 1996, 82:85-90.
6. Dagfinrud H, Hagen K: Physiotherapy interventions for ankylosing spondylitis (Cochrane Review). In the Cochrane Library, CD002822, 2001. Oxford: Update Software.
7. Sweeney S, Taylor G, Calin A: The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. J Rheumatol 2002, 29:763-766.
8. Miceli-Richard C, Dougados M: NSAIDs in ankylosing spondylitis. Clin Exp Rheumatol 2002, 20:S65-S66.
9. Stone M, Salonen D, Lax M, et al.: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001, 28:1605-1614.
10. Brandt J, Haibel H, Cornely D, et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346-1352.
11. Maksymowych WP, Jhangri GS, LeClercq S, et al.: An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998, 25:714-717.
12. van der Linden S, van Tubergen A, Hidding A: Physiotherapy in ankylosing spondylitis: what is the evidence? Clin Exp Rheumatol 2002, 20:S60-S64.
13. van Tubergen A, Boonen A, Landewe R, et al.: Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002, 47:459-467.
14. Hidding A, van der Linden S, Boer SM, et al.: Is group physical therapy superior to individualized therapy in ankylosing spondylitis? Arthritis Care Res 1993, 6:117-125.
15. Kraag G, Stokes B, Groh J, et al.: The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis: a randomized controlled trial. J Rheumatol 1990, 17:228-233.
16. Dougados M, Behier JM, Jolchine I, et al.: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001, 44:180-185.
17. Wanders A, van der Heijde, Landewe R, et al.: Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 2003, 48:233. Landmark study, only published in abstract form as yet, demonstrating that a continuous fixed dose of NSAIDs may be more beneficial than intermittent NSAIDs and may halt disease progression more.
18. Clegg DO, Reda D, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325-2329.
19. Ferraz MB, Tugwell P, Goldsmith CH, et al.: Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990, 17:1482-1486.
20. Ostendorf B, Specker C, Schneider M: Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis. J Clin Rheumatol 1998, 4:129-136.
21. van der Linden S, van der Heijde D: Clinical aspects, outcome assessment, and management of ankylosing spondylitis and post-enteric reactive arthritis. Curr Opin Rheumatol 2000, 12:263-268.
22. Sampaio-Barros PD, Costallat LT, Bertolo MB, et al.: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000, 29:160-162.
23. Biasi D, Carletto A, Caramaschi P, et al.: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000, 19:114-117.
24. Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al.: Is methotrexate effective in ankylosing spondylitis? Rheumatology 2002, 41:1330-1332.
25. Haibel H, Brandt J, Rudwaleit M, et al.: Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 2003, 42:1018-1020.
26. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al.: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.
27. Maksymowych WP, Inman RD, Gladman D, et al., Spondyloarthritis Research Consortium of Canada (SPARCC): Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003, 30:1356-1363.
28. Garret S, Jenkinson T, Kennedy LG, et al.: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
29. Calin A, Garrett S, Whitelock HC, et al.: A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2286-2291.
30. Jenkinson TR, Mallorie PA, Whitelock HC, et al.: Defining spinal mobility in ankylosing spondylitis: the Bath Ankylosing Spondylitis Metrology Index. J Rheumatol 1994, 21:1694-1698.
31. Moreira AL, Sampaio EP, Zmuidzinas A, et al.: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177:1675-1680.
32. Huang F, Gu J, Zhao W, et al.: One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002, 47:249-254.
33. Wei J, Chan T, Lin H, et al.: Thalidomide for severe refractory ankylosing spondylitis: a 6 month open-label trial. J Rheumatol 2003, 30:2627-2631.
34. Braun J, Bollow M, Neure L, et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
35. Maksymowych WP, Jhangri GS, Lambert RG, et al.: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002, 29:959-965.
36. Marzo-Ortega H, McGonagle D, O'Connor P, et al.: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001, 44:2112-2117.
37. Van den Bosch F, Kruithof E, Baeten D, et al.: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000, 59:428-433.
38. Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765.
39. Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
40. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356.
41. Brandt J, Khariouzov A, Listing J, et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.
42. Davis J Jr, van der Heijde D, Braun J: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236.
43. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF 36): conceptual framework and item selection. Med Care 1992, 30:473-483.
44. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
45. Anderson JJ, Baron G, van der HD, et al.: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
46. Braun J, Pham T, Sieper J, et al., ASAS Working Group: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
47. Stone MA, Payne U, Pacheco-Tena C, et al.: Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004, 63:84-87.
48. Wolfe F, Michaud K, Anderson J, et al.: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004, 50:372-379.
49. Feltelius N, Ekbom A, Blomqvist P: Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study. Ann Rheum Dis 2003, 62:1185-1188.
50. Carbone LD, Cooper C, Michel CJ, et al.: Ankylosing spondylitis in Rochester, Minnesota, 1935-1989: is the epidemiology changing? Arthritis Rheum 1992, 35:1476-1482.
51. Gladman DD, Brockbank J: Psoriatic arthritis. Expert Opin Investig Drugs 2000, 9:1511-1522.
52. Partsch G, Steiner G, Leeb BF, et al.: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24:518-523.
53. Ritchlin CT, Daikh BE: Recent advances in the treatment of the seronegative spondyloarthropathies. Curr Rheumatol Rep 2001, 3:399-403.
54. Danning CL, Illei GG, Hitchon C, et al.: Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000, 43:1244-1256.
55. Cuellar ML, Citera G, Espinoza LR: Treatment of psoriatic arthritis. Baillieres Clin Rheumatol 1994, 8:483-498.
56. Sarzi-Puttini P, Santandrea S, Boccassini L, et al.: The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001, 19:S17-S20.
57. Jones G, Crotty M, Brooks P: Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 1997, 36:95-99.
58. Black RL, O'Brien WM, Van Scott EJ, et al.: Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 1964, 189:743-747.
59. Wilkens RF, William JH, Ward JR, et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376-381.
60. Cutolo M, Seriolo B, Pizzorni C, et al.: Methotrexate in psoriatic arthritis. Clin Exp Rheumatol 2002, 20:S76-S80.
61. Clegg DO, Reda DJ, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996, 39:2013-2020.
62. Fraser SM, Hopkins R, Hunter JA, et al.: Sulphasalazine in the management of psoriatic arthritis. BJR 1993, 32:923-925.
63. Combe B, Goupille P, Kuntz JL, et al.: Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996, 35:664-668.
64. Gupta AK, Grober JS, Hamilton TA, et al.: Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995, 22:894-898.
65. Dougados M, van der Linden S, Leirisalo-Repo M, et al.: Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicentre, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
66. Jones G, Crotty M, Brooks P: Interventions for psoriatic arthritis (Cochrane Review). In the Cochrane Library, Issue 3, CD000212, PMID: 10908464, 2000. Oxford: Update Software.
67. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990, 33:1449-1461.
68. Ellis CN, Gorsulowsky DC, Hamtilon TA, et al.: Cyclosporine improves psoriasis in a double-blind study. JAMA 1986, 256:3110-3116.
69. Finzi AF, Mozzanica N, Cattaneo A, et al.: Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunological study. J Am Acad Dermatol 1989, 21:91-97.
70. Mahrle G, Schulze HJ, Farber L, et al.: Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995, 32:78-88.
71. Raffayova H, Rovensky J, Malis F: Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol Res 2000, 20:1-11.
72. Salvarani C, Macchioni P, Olivieri I, et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001, 28:2274-2282.
73. Manguso F, Oriente A, Peluso R, et al.: Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001, 44:S92.
74. Liang GC, Barr WG: Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001, 44:S121.
75. Kaltwasser P, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis: results from the TOPAS study [abstract]. Arthritis Rheum 2002, 46:3416.
76. Felson DT, Anderson JJ, Boers M, et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
77. Fredericksson T, Petterson U: Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978, 157:238-244.
78. Gladman D, Helliwell P, Mease PJ, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24-35. Important review of clinical outcomes in psoriatic arthritis.
79. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
80. Mease P, Kivitz A, Burch F, et al.: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001, 44:S90.
81. Antoni C, Manger B: Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002, 20:S122-S125.
82. Salvarani C, Cantini F, Olivieri I, et al.: Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003, 49:541-545.
83. Antoni C, Kavanaugh A, Kirkham B, et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. Arthritis Rheum 2002, 46:S381.
84. Utset TO, Auger JA, Peace D, et al.: Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002, 29:1907-1913.
85. Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-2784.
86. Calin A, Dijkmans B, Emery P, et al.: A multicentre placebo-controlled trial of Enbrel in ankylosing spondylitis [abstract]. Ann Rheum Dis 2003, 62:S95.